Leukapheresis Global Market Report 2025

The leukapheresis market size has grown strongly in recent years. It will grow from $66.8 billion in 2024 to $72.23 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. Growth during the historic period can be attributed to the increasing prevalence of leukemia and autoimmune diseases, rising demand for personalized medicine, advancements in stem cell research, improvements in apheresis technologies, expanding clinical trial activities, and greater awareness of immunotherapy applications.

The leukapheresis market size is expected to see strong growth in the next few years. It will grow to $97.83 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. Growth in the forecast period is expected to be driven by rising demand for personalized cell therapies, an increase in clinical trials in immuno-oncology, growing adoption in regenerative medicine, expansion of biopharmaceutical manufacturing, improved reimbursement policies, and greater awareness of cell-based research and treatment options. Key trends in the forecast period include advancements in cell separation technologies, integration of AI for optimizing procedures, development of portable leukapheresis devices, progress in cell and gene therapy, enhanced donor screening methods, and the adoption of cloud-based data tracking systems.

The growing incidence of autoimmune diseases is anticipated to drive the expansion of the leukapheresis market. Autoimmune diseases occur when the immune system mistakenly attacks the body’s healthy tissues. Factors such as reduced early-life microbial exposure and modern environmental influences are disrupting immune balance, leading to an increase in autoimmune disorders. Leukapheresis aids in treating these diseases by selectively removing harmful white blood cells that contribute to the immune system’s attack on the body. For example, according to a report by Versorgungsatlas.de, a Germany-based organization, in 2022, out of 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a prevalence rate of 8.61%. Thus, the rise in autoimmune diseases is fueling the growth of the leukapheresis market.

Leading companies in the leukapheresis market are focusing on innovations such as the development of GMP-grade leukopaks to improve the quality and efficiency of cell therapy manufacturing. GMP-grade leukopaks are leukapheresis-derived products processed under stringent good manufacturing practice (GMP) standards, ensuring high cell viability and functionality for therapeutic use. For instance, in November 2024, Sanguine Biosciences, a US-based biotechnology company, introduced LeukoCer, a GMP-grade leukopak designed to streamline workflows and speed up cell therapy development. LeukoCer provides high-quality starting materials in fresh whole or half packs, produced according to strict GMP standards, enabling researchers to advance their work and accelerate the introduction of new cell therapies to the market.

In July 2023, SCTbio, a Czech Republic-based contract development and manufacturing organization, formed a partnership with Cyto-care.eu GmbH to enhance the cryopreservation process for cell therapy in Europe. The collaboration focuses on improving the collection, cryopreservation, quality control, and logistics of leukapheresis materials, which are vital components in the production of advanced cell therapy products (ATMPs). Cyto-care.eu GmbH, based in Austria, specializes in providing cell products for biomedical research, drug discovery, and cell and gene therapy.

Major players in the leukapheresis market are Fresenius Kabi, Grifols S.A., Terumo BCT Inc., Nikkiso Co., STEMCELL Technologies Inc., Haemonetics Corporation, Macopharma, Discovery Life Sciences, BioIVT LLC, StemExpress LLC, MEDICA S.p.A, AllCells LLC, Caltag Medsystems Ltd., Miltenyi Biotec, Immune Therapy Holdings AB, Cellsep Laboratories, Accegen Biotec, Key Biologics LLC, HemaCare Corporation, Puriblood Medical, Cytopheron Technologies, and Adacyte Therapeutics.

North America was the largest region in the leukapheresis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in leukapheresis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the leukapheresis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Leukapheresis is a medical procedure that involves the separation and removal of white blood cells (leukocytes) from a patient's blood. The remaining blood components, such as red blood cells and plasma, are then returned to the body. This technique is used to treat conditions with elevated white blood cell counts or to collect specific immune cells for research or therapeutic purposes.

The main types of leukapheresis include granulocyte, lymphocyte, and monocyte apheresis. Granulocyte apheresis is a procedure that selectively isolates granulocytes (a type of white blood cell) from a patient's blood for therapeutic use. Products related to this procedure include leukapheresis devices, centrifugal devices, membrane separators, and disposables. Applications of leukapheresis extend to research areas such as cancer research, immunology, hematologic disorders, autoimmune diseases, and others. These procedures are utilized by blood component providers, blood centers, academic and research institutions, pharmaceutical and biotechnology companies, and hospitals and transfusion centers.

The leukapheresis market research report is one of a series of new reports that provides leukapheresis market statistics, including the leukapheresis industry global market size, regional shares, competitors with the leukapheresis market share, detailed leukapheresis market segments, market trends, and opportunities, and any further data you may need to thrive in the leukapheresis industry. This leukapheresis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The leukapheresis market consists of revenues earned by entities providing services such as cell collection, cell processing and storage, and custom apheresis procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The leukapheresis market also includes sales of products such as apheresis machines, centrifugal and membrane-based systems, needles & catheters, and anticoagulants and solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.